Top Story

Ocular Therapeutix announces Q2 financial results

September 2, 2014

Ocular Therapeutix has announced its second-quarter financial results, which included a net loss attributable to common stockholders of approximately $6.4 million, or $2.10 per share, compared with $3.1 million, or $1.19 per share, during the same time last year.

Q2 financial results also included $3.4 million in non-cash charges for stock-based compensation and licensing and consultant fees paid in common stock, compared with $0.2 million for similar charges in 2013, according to a company press release.

In the Journals

Fenofibrate slows diabetic retinopathy progression in at-risk patients

September 2, 2014
Intensive treatment of glycemia and dyslipidemia slowed the progression of diabetic retinopathy in diabetic patients with cardiovascular disease or associated risk…

Allergan responds to Valeant, Pershing Square counterclaims

September 2, 2014
Allergan has filed an answer in the U.S. District Court for the Central District of California in response to Valeant Pharmaceuticals and Pershing Square Capital…
Breaking News

Ozurdex approved in EU for treatment of DME

September 2, 2014
The European Commission has extended marketing authorization for Ozurdex for the treatment of diabetic macular edema in certain patients, according to an Allergan press…
More News Headlines »

Managing associate optometrists in your practice, part 4

July 31, 2014
As with eye surgeons, not all optometrists are created equally. It’s a broad but true generalization that younger…
More »
Meeting News Coverage Video

Speaker discusses HOME study

August 13, 2014
At the American Society of Retina Specialists meeting in San Diego, David S. Boyer, MD, discusses results from the HOME…
More »